None listed
Conditions
Brief summary
This study assesses the impact of Clonidine a commonly prescribed medication for the treatment of Attention Deficit hyperactivity Disorder (ADHD) on behavioural and brain imaging measures of cognition. Specifically, it measures the impact of Clonidine on key behaviours that are altered in ADHD including, response inhibition, attention and error processing.
Interventions
A randomised placebo controlled trial of the effects of Clonidine (200mcg) on cognitive control and error processing measures in healthy adults.
Clonidine trade name: Catapress
Participants will receive each of Clonidine and placebo in capsule form (1 week apart, order of administration randomised).
The Experimenter will observe ingestion of the capsule (time 0), participants will commence tasks after 90 minutes has elapsed (onset of drug peak), task will be completed at 180 minutes, observa
A randomised placebo controlled trial of the effects of Clonidine (200mcg) on cognitive control and error processing measures in healthy adults. Clonidine trade name: Catapress Participants will receive each of Clonidine and placebo in capsule form (1 week apart, order of administration randomised). The Experimenter will observe ingestion of the capsule (time 0), participants will commence tasks after 90 minutes has elapsed (onset of drug peak), task will be completed at 180 minutes, observation will then occur for half an hour before completion at 210 minutes.
Sponsors
Professor Mark Bellgrove
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
Male
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
healthy adult Normal or corrected to normal vision
Exclusion criteria
History of psychiatric illness Currently on medication Smoker Regular recreational drug use
Outcome results
None listed